Lung Cancer
From the Journals
Pulmonary metastasectomy may be useful for soft-tissue sarcoma spread
When is lung metastasectomy best for soft tissue sarcoma?
From the Journals
Immune signature shows good prognostic performance in early-stage NSCLC
Patients in the signature-defined high-risk group had roughly twice the adjusted risk of death as that of those in the signature-defined low-risk...
From the Journals
Cancer immunotherapy seen repigmenting gray hair
Patients treated for lung cancer saw a surprising side effect – the return of their previous hair color.
Clinical Review
Molecular Markers and Targeted Therapies in the Management of Non-Small Cell Lung Cancer
Conference Coverage
Dacomitinib boosts PFS in advanced NSCLC
CHICAGO – In a phase III trial, the dacomitinib arm had triple the PFS rate of the gefitinib arm (30.6% versus 9.6%) at 2 years.
Original Report
Physician attitudes and prevalence of molecular testing in lung cancer
News
FDA approves dabrafenib and trametinib for BRAF V600E+ metastatic NSCLC
The FDA also approved a next-generation sequencing test to detect BRAF and other mutations from a single tissue specimen.
Conference Coverage
T-DMI doesn’t wow in HER2-overexpressing NSCLC
CHICAGO –Beyond its role in advanced breast cancer, the antibody-drug conjugate ado-trastuzumab-emtansine (T-DM1; Kadcyla) showed modest activity...
Conference Coverage
Lung cancer linked to suicide
WASHINGTON – A cardiothoracic surgeon presents the differences in suicide rates among U.S. patients living with various kinds of cancer.
Conference Coverage
Alectinib in ALK+ NSCLC is a watershed moment
CHICAGO – In what’s being hailed as practice-changing findings, the anaplastic lymphoma kinase inhibitor alectinib (Alecensa) was associated with...
Conference Coverage
VIDEO: Immunotherapy ups disease control rate in relapsed mesothelioma
CHICAGO – Early data from a phase II trial of immune checkpoint inhibitors to treat relapsed mesothelioma give hope that immunotherapy may be an...